ClinicalTrials.gg
CompletedNCT01889186Updated Dec 16, 2021Results posted

A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion

A Phase 2 interventional study of ABT-199 (Main Cohort) and ABT-199 (Safety Expansion Cohort) in Chronic Lymphocytic Leukemia, 17p Deletion and Cancer of the Blood and Bone Marrow, sponsored by AbbVie. Completed at 48 sites in 7 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2021-12-16.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
158
Allocation
Non-randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell — 21 open to participants now, 42 under way, 8 of them phase 3. venetoclax · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
20th of 69
158 · median 72
Started
2013
the only one that year
Phase 2
41 of 69
16 open now
Registered
5th of 69
by date
Lead sponsor
11 of 69
AbbVie

Among the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 20th largest by enrollment, is the only one that started in 2013, is one of 41 in phase 2, and was the 5th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

21 of the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This was an open-label, multicenter, global study to determine the efficacy of ABT-199 (Venetoclax) monotherapy in participants with relapsed/refractory (R/R) or previously untreated chronic lymphocytic leukemia (CLL) harboring 17p deletion.

Read the detailed description

This study was designed to enroll approximately 150 participants in 2 cohorts: a main cohort of approximately 100 participants, and a safety expansion (SE) cohort of approximately 50 participants. The primary objective of the main cohort was to evaluate the efficacy of ABT-199 monotherapy in participants with R/R CLL harboring the 17p deletion. The primary objective of the safety expansion cohort was to evaluate the safety of ABT-199 in approximately 50 participants with R/R CLL harboring 17p deletion treated per updated tumor lysis syndrome (TLS) prophylaxis and management measures.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • 17p Deletion
  • Cancer of the Blood and Bone Marrow

Keywords

  • Chronic Lymphocytic Leukemia
  • 17p Deletion
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be greater than or equal to 18 years of age.
  • Participant must have diagnosis of chronic lymphocytic leukemia (CLL) that meets published 2008 Modified IWCLL NCI-WG (International Workshop for Chronic Lymphocytic Leukemia National Cancer Institute-Working Group) Guidelines.

    • Participant has an indication for treatment according to the 2008 Modified IWCLL NCI WG Guidelines;
    • Participant has clinically (lymphocytosis > 5 × 10\^9/L and/or palpable and measurable nodes by physical exam and/or organomegaly assessed by physical exam);
    • Participant must be or have relapsed after receiving at least one (participants that have progressed after 1 cycle of treatment or have completed at least 2 cycles of treatment for a given line of therapy) or previously untreated CLL (previously untreated CLL participants must have received no prior chemotherapy or immunotherapy. Participants with a history of emergency, loco-regional radiotherapy (e.g., for relief of compressive signs or symptoms) are eligible. In addition, participants must meet the CLL diagnostic criteria above and must have > 5 × 10\^9/L B-Lymphocytes in the peripheral blood.);
    • Participants must have 17p deletion, assessed by local laboratory (in bone marrow or peripheral blood) or assessed by central laboratory (peripheral blood).
  • Participant has an (ECOG) performance score of less than or equal to 2.
  • Participant must have adequate bone marrow function at Screening as follows:

    • (ANC) greater than or equal to 1000/µL, or
    • For subjects with an ANC less than 1000/µL at Screening and bone marrow heavily infiltrated with underlying disease (unless cytopenia is clearly due to marrow involvement of CLL), growth factor support may be administered after Screening and prior to the first dose of ABT-199 to achieve the ANC eligibility criteria (greater than or equal to 1000/µL);
    • greater than 30,000/mm\^3 (without transfusion support within 14 days of Screening, without evidence of mucosal bleeding, without known history of bleeding episode within 3 months of Screening, and without history of bleeding disorder);
    • greater than or equal to 8.0 g/dL.
  • Participant must have adequate coagulation, renal, and hepatic function, per laboratory reference range at Screening as follows:

    • (aPTT) and prothrombin time (PT) not to exceed 1.5 × the ;
    • Calculated greater than 50 mL/min using 24-hour Creatinine Clearance or modified Cockcroft-Gault equation (using Ideal Body Mass [IBM] instead of Mass). For participants that have (BMI) of > 30 kg/m\^2 or \< 19 kg/m\^2, 24-hour measured urine creatinine clearance is required;
    • (AST) and alanine aminotransferase (ALT) less than or equal to 3.0 × the upper normal limit of institution's normal range; less than or equal to 1.5 × upper limit of normal. Participants with Gilbert's Syndrome may have a bilirubin greater 1.5 × upper limit of normal, per correspondence between the investigator and AbbVie medical monitor.
  • For participants at high risk of tumor lysis syndrome a pre-approval by the AbbVie medical monitor is required prior to enrollment.

Exclusion criteria

Exclusion Criteria:

  • Participant has undergone an stem cell transplant.
  • Participant has developed Richter's transformation confirmed by .
  • Participant has prolymphocytic leukemia.
  • Participant has active and uncontrolled cytopenias (for 2 weeks prior to Screening), including autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura despite low dose .
  • Participant has previously received ABT-199.
  • Participant has received a biologic agent for anti-neoplastic intent within 30 days prior to the first dose of study drug.
  • Participant has received any of the following within 14 days or 5 half-lives as applicable prior to the first dose of study drug, or has not recovered to less than Common Toxicity Criteria (CTC) grade 2 adverse effect(s)/toxicity(s) of the previous therapy:

    • Any anti-cancer therapy including chemotherapy, or radiotherapy;
    • therapy, including targeted small molecule agents.
  • Participant has known allergy to both xanthine oxidase inhibitors and rasburicase.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
158 participants (actual)

Study arms

  • Experimental
    Main Cohort

    Participants received ABT-199 tablets once daily (QD) orally for up to 79 months. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.

    Drug: ABT-199 (Main Cohort)

  • Experimental
    Safety Expansion Cohort

    Participants received ABT-199 tablets once daily (QD) orally for up to 68 months. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.

    Drug: ABT-199 (Safety Expansion Cohort)

Interventions

  • Participants received a test dose of ABT-199 of ≤ 20 mg on Week 1 Day 1 of the Lead-In Period. For those with significant electrolyte and/or lymphocyte changes within 24 hours of the first dose, the 20 mg dose was maintained for 7 days with escalation to 50 mg on Week 2 Day 1. If none of the electrolyte and/or lymphocyte changes occurred within 24 hours from ABT-199 20 mg dose administration, the participant was dose-escalated to 50 mg on Week 1 Day 2. After the first dose of 50 mg, if no laboratory abnormalities occurred, the participant remained on the 50 mg dose through Week 1. After receiving the 50 mg dose for approximately 1 week (6 to 7 days), the following dose escalation proceeded with weekly increases in dose: → 100 mg → 200 mg → 400 mg (or additional lead-in steps to designated 400 mg dose), as tolerated.

    Also known as: Venetoclax, GDC-0199

  • Participants received an initial dose of ABT-199 of 20 mg on Week 1 Day 1 of the Lead-In Period. If one or more electrolyte changes (from the 0 hr measurement prior to dosing) suggestive of laboratory tumor lysis syndrome (LTLS) or clinical TLS (CTLS) occurred within 24 hours of the 20 mg dose, no additional doses were administered until resolution. Upon resolution of laboratory abnormalities, the 20 mg dose was continued through Week 1. If no significant findings suggestive of clinical or laboratory TLS occurred within 24 hours, the 20 mg dose was continued through Week 1 Day 7, and escalated to a dose of 50 mg on Week 2 Day 1. Those who had drug interruptions may have been allowed to escalate to and be maintained at 50 mg for 1 week after they had been on a 20 mg dose for at least 1 week (5 - 7 days). After a week at 50 mg, weekly dose escalations were implemented as follows: 100 mg → 200 mg → 400 mg (or additional lead-in steps to designated 400 mg dose) as tolerated.

    Also known as: Venetoclax, GDC-0199

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (Main Cohort)

    The overall response rate (ORR) is defined as the proportion of participants with an overall response (complete remission \[CR\] + complete remission with incomplete marrow recovery \[CRi\] + nodular partial remission \[nPR\] + partial remission \[PR\]) per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria as assessed by the Independent Review Committee (IRC) in the first 70 participants treated in the Main Cohort.

    Time frame: Up to 36 weeks

  2. Number of Participants With Adverse Events (Safety Expansion Cohort)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

    Time frame: From the first dose of study drug until 30 days following last dose of study drug (up to 69 months)

Secondary outcomes

  1. Overall Response Rate (ORR) (Safety Expansion Cohort)

    The overall response rate (ORR) is defined as the proportion of participants with an overall response (complete remission \[CR\] + complete remission with incomplete marrow recovery \[CRi\] + nodular partial remission \[nPR\] + partial remission \[PR\]) per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria.

    Time frame: Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up

  2. Complete Remission (CR) Rate

    Complete remission was defined as the proportion of participants who achieved a CR or Complete Remission with Incomplete Marrow Recovery(CRi ) per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria. Participants who did not achieve a CR or CRi were considered to be non-responders in the calculation of CR rate.

    Time frame: Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up

  3. Partial Remission (PR) Rate

    PR rate was defined as the proportion of participants who achieved a nodular partial remission (nPR) or PR per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria. Participants who did not achieve a nPR or PR were considered to be non-responders in the calculation of PR rate.

    Time frame: Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up

  4. Duration of Overall Response

    Duration of overall response (DoR) was defined as the number of days from the date of first response (CR, CRi, nPR, or PR) by either CT scan or physical exam determination to the earliest recurrence (progressive disease; PD) or death. For participants who had a PR before CR, CRi, or nPR in subsequent visits, the DoR was computed from the earliest PR. If a participant was still responding, then their data was censored at the date of their last available disease assessment. To be included in the DoR analysis, participants must have had a response per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria (CR, CRi, confirmed nPR, or confirmed PR). For participants who never experienced response, their data was not included in the analysis.

    Time frame: Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up

  5. Progression-free Survival

    Duration of progression-free survival (PFS) was defined as the number of days from the date of first dose to the date of earliest disease progression or death. All disease progression was included regardless of whether the event occurred while the participant was taking ABT-199 or had previously discontinued ABT-199. If the participant does not experience disease progression or death, then the data was censored at the date of last disease assessment. Data for participants without any disease assessments performed after the baseline visit were censored at the date of first dose plus 1 day.

    Time frame: Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up

  6. Event-free Survival

    Event-free survival (EFS) was defined as the number of days from the date of first dose to the date of earliest disease progression, death, or start of a new anti-leukemic therapy. If the specified event (disease progression, death, start of a new anti-leukemic treatment) did not occur, participants were censored at the date of last disease assessment. Data for participants without any disease assessments performed after the baseline visit were censored at the date of first dose plus 1 day.

    Time frame: Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up

  7. Time to Progression

    Time to progression (TTP) was defined as the number of days from the date of first dose to the date of earliest disease progression. All disease progression was included regardless of whether the event occurred while the participant was taking ABT-199 or had previously discontinued ABT-199. If the participant did not experience disease progression, then the data was censored at the date of last available disease assessment. Data for participants without any disease assessments performed after the baseline visit were censored at the date of first dose plus 1 day.

    Time frame: Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up

  8. Time to First Response

    Time to first response was defined as the number of days from the date of first dose to the date of the first sign of response (CR, CRi, nPR, or PR) given the participant has had a CR, CRi, confirmed nPR, or confirmed PR per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria. The first response could have been an assessment by physical exam as long as the results were later confirmed per the 2008 Modified IWCLL NCI-WG criteria. For participants who never experienced a response, the participant's data were not included in the analysis.

    Time frame: Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up

  9. Time to 50% Reduction in Absolute Lymphocyte Count

    Time to 50% reduction in absolute lymphocyte count (ALC) was defined as the number of days (hours if applicable) from the date of first dose to the date when the ALC had reduced to 50% of the baseline value. Only participants with a baseline of ALC \> 5 × 10\^9 /L were included in the analysis. For participants who never achieved a 50% reduction in ALC, the participant's data were not included in the analysis.

    Time frame: Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up

  10. Overall Survival

    Overall survival (OS) was defined as number of days from the date of first dose to the date of death. For participants who did not die, their data was censored at the date of last study visit or the last known date to be alive, whichever was later.

    Time frame: Up to the data cutoff date of 15 December 2020, approximately 7.5 years of follow-up

  11. Percentage of Participants Who Moved on to Stem Cell Transplant

    The percentage of participants who moved on to stem cell transplant was summarized.

    Time frame: Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up

07

Results

Posted Dec 16, 2021

Participant flow

Participant flow — Overall Study
MilestoneMain CohortSafety Expansion Cohort
Started10751
Completed00
Not completed10751
Withdrew: Adverse event- not related to progression185
Withdrew: Adverse event- related to progression72
Withdrew: Covid-19 logistical restrictions10
Withdrew: Investigator request11
Withdrew: Progressive disease- richter's127
Withdrew: Progressive disease per protocol4617
Withdrew: Stem cell transplant21
Withdrew: Withdrew consent23
Withdrew: Other, not specified1815

Outcome measures

PrimaryOverall Response Rate (Main Cohort)

The overall response rate (ORR) is defined as the proportion of participants with an overall response (complete remission \[CR\] + complete remission with incomplete marrow recovery \[CRi\] + nodular partial remission \[nPR\] + partial remission \[PR\]) per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria as assessed by the Independent Review Committee (IRC) in the first 70 participants treated in the Main Cohort.

Time frame:
Up to 36 weeks
Reported as:
Number · percentage of participants
Overall Response Rate (Main Cohort)
percentage of participantsMain Cohort
Overall Response Rate (Main Cohort)77.1 (65.6 to 86.3)
Statistical analysis
  • Main Cohort · Clopper-Pearson exact method · p = <0.001
PrimaryNumber of Participants With Adverse Events (Safety Expansion Cohort)

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

Time frame:
From the first dose of study drug until 30 days following last dose of study drug (up to 69 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (Safety Expansion Cohort)
ParticipantsSafety Expansion Cohort
Number of Participants With Adverse Events (Safety Expansion Cohort)51
SecondaryOverall Response Rate (ORR) (Safety Expansion Cohort)

The overall response rate (ORR) is defined as the proportion of participants with an overall response (complete remission \[CR\] + complete remission with incomplete marrow recovery \[CRi\] + nodular partial remission \[nPR\] + partial remission \[PR\]) per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria.

Time frame:
Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) (Safety Expansion Cohort)
percentage of participantsSafety Expansion Cohort
Overall Response Rate (ORR) (Safety Expansion Cohort)82.4 (69.1 to 91.6)
SecondaryComplete Remission (CR) Rate

Complete remission was defined as the proportion of participants who achieved a CR or Complete Remission with Incomplete Marrow Recovery(CRi ) per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria. Participants who did not achieve a CR or CRi were considered to be non-responders in the calculation of CR rate.

Time frame:
Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up
Reported as:
Number · percentage of participants
Complete Remission (CR) Rate
percentage of participantsMain CohortSafety Expansion Cohort
Complete Remission (CR) Rate21.5 (14.1 to 30.5)27.5 (15.9 to 41.7)
SecondaryPartial Remission (PR) Rate

PR rate was defined as the proportion of participants who achieved a nodular partial remission (nPR) or PR per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria. Participants who did not achieve a nPR or PR were considered to be non-responders in the calculation of PR rate.

Time frame:
Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up
Reported as:
Number · percentage of participants
Partial Remission (PR) Rate
percentage of participantsMain CohortSafety Expansion Cohort
Partial Remission (PR) Rate53.3 (43.4 to 63.0)54.9 (40.3 to 68.9)
SecondaryDuration of Overall Response

Duration of overall response (DoR) was defined as the number of days from the date of first response (CR, CRi, nPR, or PR) by either CT scan or physical exam determination to the earliest recurrence (progressive disease; PD) or death. For participants who had a PR before CR, CRi, or nPR in subsequent visits, the DoR was computed from the earliest PR. If a participant was still responding, then their data was censored at the date of their last available disease assessment. To be included in the DoR analysis, participants must have had a response per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria (CR, CRi, confirmed nPR, or confirmed PR). For participants who never experienced response, their data was not included in the analysis.

Time frame:
Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up
Reported as:
Median · months
Duration of Overall Response
monthsMain CohortSafety Expansion Cohort
Duration of Overall Response35.3 (26.5 to NA)NA (27.3 to NA)
SecondaryProgression-free Survival

Duration of progression-free survival (PFS) was defined as the number of days from the date of first dose to the date of earliest disease progression or death. All disease progression was included regardless of whether the event occurred while the participant was taking ABT-199 or had previously discontinued ABT-199. If the participant does not experience disease progression or death, then the data was censored at the date of last disease assessment. Data for participants without any disease assessments performed after the baseline visit were censored at the date of first dose plus 1 day.

Time frame:
Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up
Reported as:
Median · months
Progression-free Survival
monthsMain CohortSafety Expansion Cohort
Progression-free Survival24.7 (21.7 to 35.9)30.2 (24.7 to NA)
SecondaryEvent-free Survival

Event-free survival (EFS) was defined as the number of days from the date of first dose to the date of earliest disease progression, death, or start of a new anti-leukemic therapy. If the specified event (disease progression, death, start of a new anti-leukemic treatment) did not occur, participants were censored at the date of last disease assessment. Data for participants without any disease assessments performed after the baseline visit were censored at the date of first dose plus 1 day.

Time frame:
Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up
Reported as:
Median · months
Event-free Survival
monthsMain CohortSafety Expansion Cohort
Event-free Survival24.7 (19.7 to 35.9)30.2 (24.7 to NA)
SecondaryTime to Progression

Time to progression (TTP) was defined as the number of days from the date of first dose to the date of earliest disease progression. All disease progression was included regardless of whether the event occurred while the participant was taking ABT-199 or had previously discontinued ABT-199. If the participant did not experience disease progression, then the data was censored at the date of last available disease assessment. Data for participants without any disease assessments performed after the baseline visit were censored at the date of first dose plus 1 day.

Time frame:
Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up
Reported as:
Median · months
Time to Progression
monthsMain CohortSafety Expansion Cohort
Time to Progression28.2 (21.9 to 39.0)30.2 (27.0 to NA)
SecondaryTime to First Response

Time to first response was defined as the number of days from the date of first dose to the date of the first sign of response (CR, CRi, nPR, or PR) given the participant has had a CR, CRi, confirmed nPR, or confirmed PR per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria. The first response could have been an assessment by physical exam as long as the results were later confirmed per the 2008 Modified IWCLL NCI-WG criteria. For participants who never experienced a response, the participant's data were not included in the analysis.

Time frame:
Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up
Reported as:
Mean · months
Time to First Response
monthsMain CohortSafety Expansion Cohort
Time to First Response1.1 (1.0 to 1.3)1.3 (1.1 to 1.5)
SecondaryTime to 50% Reduction in Absolute Lymphocyte Count

Time to 50% reduction in absolute lymphocyte count (ALC) was defined as the number of days (hours if applicable) from the date of first dose to the date when the ALC had reduced to 50% of the baseline value. Only participants with a baseline of ALC \> 5 × 10\^9 /L were included in the analysis. For participants who never achieved a 50% reduction in ALC, the participant's data were not included in the analysis.

Time frame:
Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up
Reported as:
Mean · weeks
Time to 50% Reduction in Absolute Lymphocyte Count
weeksMain CohortAll Treated Participants
Time to 50% Reduction in Absolute Lymphocyte Count1.1 (0.9 to 1.2)1.2 (1.1 to 1.4)
SecondaryOverall Survival

Overall survival (OS) was defined as number of days from the date of first dose to the date of death. For participants who did not die, their data was censored at the date of last study visit or the last known date to be alive, whichever was later.

Time frame:
Up to the data cutoff date of 15 December 2020, approximately 7.5 years of follow-up
Reported as:
Median · months
Overall Survival
monthsMain CohortSafety Expansion Cohort
Overall Survival53.4 (37.0 to 73.0)NA (61.6 to NA)
SecondaryPercentage of Participants Who Moved on to Stem Cell Transplant

The percentage of participants who moved on to stem cell transplant was summarized.

Time frame:
Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up
Reported as:
Number · percentage of participants
Percentage of Participants Who Moved on to Stem Cell Transplant
percentage of participantsMain CohortAll Treated Participants
Percentage of Participants Who Moved on to Stem Cell Transplant2.8 (0.6 to 8.0)2.5 (0.7 to 6.4)

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from the first dose of study drug until 30 days after last study drug administration, up to 80 months for the Main Cohort and up to 69 months for the Safety Expansion Cohort.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Main Cohort62/107 (57.9%)78/107 (72.9%)103/107 (96.3%)
Safety Expansion Cohort19/51 (37.3%)34/51 (66.7%)50/51 (98%)
Most frequent serious events
Showing 10 of 187
Most frequent serious events
EventMain CohortSafety Expansion Cohort
MALIGNANT NEOPLASM PROGRESSIONNeoplasms benign, malignant and unspecified (incl cysts and polyps)18/1074/51
PNEUMONIAInfections and infestations14/1078/51
PYREXIAGeneral disorders8/1070/51
AUTOIMMUNE HAEMOLYTIC ANAEMIABlood and lymphatic system disorders7/1071/51
FEBRILE NEUTROPENIABlood and lymphatic system disorders7/1072/51
TUMOUR LYSIS SYNDROMEMetabolism and nutrition disorders2/1073/51
NEUTROPENIABlood and lymphatic system disorders2/1072/51
MYOCARDIAL INFARCTIONCardiac disorders1/1072/51
DIARRHOEAGastrointestinal disorders0/1072/51
LOWER RESPIRATORY TRACT INFECTIONInfections and infestations2/1072/51
Most frequent other events
Showing 10 of 69
Most frequent other events
EventMain CohortSafety Expansion Cohort
DIARRHOEAGastrointestinal disorders42/10726/51
NAUSEAGastrointestinal disorders35/10724/51
NEUTROPENIABlood and lymphatic system disorders47/10722/51
FATIGUEGeneral disorders27/10716/51
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations22/10715/51
COUGHRespiratory, thoracic and mediastinal disorders16/10714/51
ANAEMIABlood and lymphatic system disorders27/10711/51
HEADACHENervous system disorders16/10712/51
THROMBOCYTOPENIABlood and lymphatic system disorders24/1079/51
NASOPHARYNGITISInfections and infestations19/1078/51

Baseline characteristics

All treated participants: all participants who received at least one dose of ABT-199 in either the Main Cohort or Safety Expansion Cohort

Age, Continuous
Age, Continuous(years)Main CohortSafety Expansion CohortTotal
Mean65.7 ± 9.8765.4 ± 9.9765.6 ± 9.87
Sex: Female, Male
Sex: Female, Male(Participants)Main CohortSafety Expansion CohortTotal
Female372259
Male702999
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Main CohortSafety Expansion CohortTotal
White10349152
Black314
Asian000
American Indian/Alaska Native000
Native Hawaiian or other Pacific Islander000
Other000
Multi race000
MISSING112
08

Study locations

48 sites
  • University of Arizona Cancer Center - North Campus /ID# 96748
    Tucson, Arizona 85719-1478, United States
  • City of Hope /ID# 112875
    Duarte, California 91010, United States
  • Moore UC San Diego Cancer Center /ID# 91793
    La Jolla, California 92093, United States
  • Stanford University School of Med /ID# 105117
    Stanford, California 94305-2200, United States
  • Georgetown University Hospital /ID# 96954
    Washington, District of Columbia 20007, United States
  • Northwestern University Feinberg School of Medicine /ID# 92499
    Chicago, Illinois 60611-2927, United States
  • The University of Chicago Medical Center /ID# 96960
    Chicago, Illinois 60637-1443, United States
  • Ingalls Memorial Hosp /ID# 92497
    Harvey, Illinois 60426, United States
  • Dana-Farber Cancer Institute /ID# 92494
    Boston, Massachusetts 02215, United States
  • Henry Ford Health System /ID# 97795
    Detroit, Michigan 48202, United States
  • Hackensack Univ Med Ctr /ID# 92500
    Hackensack, New Jersey 07601, United States
  • Rutgers Cancer Institute of New Jersey /ID# 92513
    New Brunswick, New Jersey 08903, United States
  • Columbia Univ Medical Center /ID# 103835
    New York, New York 10032-3725, United States
  • Columbia Univ Medical Center /ID# 94716
    New York, New York 10032-3725, United States
  • Cleveland Clinic Main Campus /ID# 92495
    Cleveland, Ohio 44195, United States
  • University of Texas MD Anderson Cancer Center /ID# 92521
    Houston, Texas 77030, United States
  • Royal North Shore Hospital /ID# 98836
    St Leonards, New South Wales 2065, Australia
  • John Fawkner Private Hospital /ID# 98835
    Coburg, Victoria 3058, Australia
  • Peter MacCallum Cancer Ctr /ID# 91795
    Melbourne, Victoria 3000, Australia
  • Royal Melbourne Hospital /ID# 91794
    Parkville, Victoria 3050, Australia
  • Duplicate_Jewish General Hospital /ID# 99476
    Montreal, Quebec H3T 1E2, Canada
  • Centre Hospitalier Lyon Sud /ID# 98839
    Pierre Benite CEDEX, Auvergne-Rhone-Alpes 69495, France
  • Hopital Avicenne - APHP /ID# 98840
    Bobigny, Ile-de-France 93000, France
  • Hopital Pitie Salpetriere /ID# 98842
    Paris, 75651, France
  • Centre Henri Becquerel /ID# 98838
    Rouen, 76038, France
  • Universitaetsklinik Heidelberg /ID# 98845
    Heidelberg, Baden-Wuerttemberg 69120, Germany
  • Uniklinik Koeln /ID# 98847
    Köln, Nordrhein-Westfalen 50937, Germany
  • Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 113235
    Kiel, Schleswig-Holstein 24105, Germany
  • Universitaetsklinikum Ulm /ID# 92533
    Ulm, Thueringen 89081, Germany
  • Universitaetsklinikum Carl Gustav Carus an der TU Dresden /ID# 113256
    Dresden, 01307, Germany
  • Universitaetsklinikum Freiburg /ID# 113276
    Freiburg, 79106, Germany
  • Universitaetsmedizin Goettingen /ID# 113258
    Göttingen, 37075, Germany
  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz /ID# 113236
    Mainz, 55131, Germany
  • Muenchen Klinik Schwabing /ID# 113275
    Muenchen, 80804, Germany
  • Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie /ID# 98848
    Lublin, Lubelskie 20-081, Poland
  • SP ZOZ Szpital Uniwersytecki w Krakowie /ID# 98849
    Krakow, Malopolskie 31-501, Poland
  • Szpital Wojewodzki w Opolu /ID# 102855
    Opole, Opolskie 46-020, Poland
  • Leicester Royal Infirmary /ID# 98865
    Leicester, England LE1 5WW, United Kingdom
  • The Royal Bournemouth Hospital /ID# 118975
    Bournemouth, BH7 7DW, United Kingdom
  • Addenbrookes Hospital /ID# 119977
    Cambridge, CB2 0SP, United Kingdom
  • St. James University Hospital /ID# 98863
    Leeds, LS9 7TF, United Kingdom
  • Royal Liverpool and Broadgreen /ID# 98860
    Liverpool, L7 8XP, United Kingdom
  • St Bartholomew's Hospital, Bar /ID# 98862
    London, EC1A 7BE, United Kingdom
  • King's College Hospital NHS Foundation Trust /ID# 119975
    London, SE5 9RS, United Kingdom
  • The Christie Hospital /ID# 98864
    Manchester, M20 4BX, United Kingdom
  • Oxford Univ Hosp NHS Trust /ID# 119976
    Oxford, OX3 7LE, United Kingdom
  • Derriford Hospital /ID# 118335
    Plymouth, PL6 8DH, United Kingdom
  • Royal Marsden Hospital /ID# 98861
    Sutton, SM2 5PT, United Kingdom
09

References and documents

Publications

  • Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, Puvvada SD, Wendtner CM, Roberts AW, Jurczak W, Mulligan SP, Bottcher S, Mobasher M, Zhu M, Desai M, Chyla B, Verdugo M, Enschede SH, Cerri E, Humerickhouse R, Gordon G, Hallek M, Wierda WG. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016 Jun;17(6):768-778. doi: 10.1016/S1470-2045(16)30019-5. Epub 2016 May 10. PubMed 27178240 ↗
  • Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, Hallek M, Byrd JC, Humphrey K, Zhou L, Chyla B, Nielsen J, Potluri J, Kim SY, Verdugo M, Stilgenbauer S, Wierda WG, Seymour JF. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood. 2019 Jul 11;134(2):111-122. doi: 10.1182/blood.2018882555. Epub 2019 Apr 25. PubMed 31023700 ↗
  • Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, Jurczak W, Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, Bottcher S, Zhou L, Salem AH, Desai M, Chyla B, Arzt J, Kim SY, Verdugo M, Gordon G, Hallek M, Wierda WG. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol. 2018 Jul 1;36(19):1973-1980. doi: 10.1200/JCO.2017.76.6840. Epub 2018 May 1. Erratum In: J Clin Oncol. 2019 Sep 1;37(25):2299. doi: 10.1200/JCO.19.00384. PubMed 29715056 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2013 to primary completion in Oct 2020, 88 months.

Results were first posted in Dec 2021, 1 year 1 month after primary completion.

Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's 88 months is above that.

Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2013
First posted
Jun 28, 2013
StartActual
Jun 27, 2013
Primary completionActual
Oct 28, 2020
CompletionActual
Dec 15, 2020
Results first posted
Dec 16, 2021
Last update
Dec 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01889186
Lead sponsor
AbbVie
Collaborators
Genentech, Inc.
Responsible party
Sponsor
First posted
Jun 28, 2013
Start date
Jun 27, 2013
Primary completion
Oct 28, 2020
Completion
Dec 15, 2020
Results posted
Dec 16, 2021
Last update
Dec 16, 2021

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion